People who are moderately to severely immunocompromised should receive a third dose of vaccine. The first group to be provided with a third dose are those most severely immunocompromised. The first group includes :
Solid organ transplant
People who have had a solid organ transplant.
Treatment for lymphoma or malignant hematologic conditions
People who received treatment for lymphoma or malignant hematologic conditions (like myeloma or leukemia) in January 2021 or later.
People who received treatment since January 2020 with any anti-CD20 agents (such as rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab).
B-cell depleting agents
People who have been treated since January 2020 with b-cell depleting agents (such as epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, Atacicept, anti-BR3, alemtuzumab).
Combined immune deficiencies
People with combined immune deficiencies affecting T-cells, immune dysregulation or type 1 interferon defects.
Bone marrow or stem cell transplant
People who had bone marrow or stem cell transplant in September 2019 or later, or are still taking immunosuppressant medications related to transplant.
People who are moderately immunocompromised due to other conditions or treatments may be invited to receive a 3rd dose at a later time. This information will be updated soon. For now. only those with a condition or treatment listed above will be eligible for a 3rd dose.